TG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Beats Estimates By $0.07 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07, Zacks reports. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

TG Therapeutics Trading Up 3.5 %

Shares of TGTX opened at $35.62 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 12 month low of $12.93 and a 12 month high of $36.94. The stock has a market cap of $5.54 billion, a PE ratio of -356.16 and a beta of 2.30. The stock’s 50-day moving average is $30.86 and its two-hundred day moving average is $28.33.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.